Secondary Hyperparathyroidism In Dialysis Patients Therapeutics
1. Hectorol patent expiration
Treatment: Reduction of elevated ipth levels in the mgt of secondary hyperparathyroidism in patients undergong chronic renal dialysis
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6903083 | SANOFI | Stabilized hydroxyvitamin D |
Jul, 2021
(4 years ago) | |
| US5602116 | SANOFI | Method for treating and preventing secondary hyperparathyroidism |
Feb, 2014
(11 years ago) | |
| US7148211 | SANOFI | Formulation for lipophilic agents |
Sep, 2023
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-14) | Jun 11, 2028 |
Drugs and Companies using DOXERCALCIFEROL ingredient
Market Authorisation Date: 23 April, 2004
Dosage: CAPSULE; INJECTABLE
How can I launch a generic of HECTOROL before it's drug patent expiration?
More Information on Dosage
HECTOROL family patents
